SCHEMBL30869796

SCHEMBL30869796

c1cc2c(cc1-c1ccc3[nH]ncc3c1)Oc1cc(-c3ccc4[nH]ncc4c3)ccc1N2CCCN1CC2(COC2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.42
EGFR P00533 2/20 0.41
GSK3B P49841 6/20 0.38
CDK5 Q00535 6/20 0.38
DYRK1A Q13627 6/20 0.38
CLK2 P49760 3/20 0.38
CLK4 Q9HAZ1 3/20 0.38
CLK1 P49759 2/20 0.38
DYRK3 O43781 2/20 0.38
DYRK1B Q9Y463 2/20 0.38
CLK3 P49761 1/20 0.38
CDK5R1 Q15078 1/20 0.38
DYRK2 Q92630 1/20 0.38
ROCK1 Q13464 6/20 0.37
DAPK3 O43293 5/20 0.37
ROCK2 O75116 5/20 0.37
CDK2 P24941 4/20 0.37
AURKA O14965 4/20 0.37
GSK3A P49840 4/20 0.37
CDK1 P06493 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869426 0.98 GRIA1 (0.42) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869822 0.97 GRIA1 (0.41) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869445 0.94 GRIA1 (0.43) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869455 0.92 GRIA1 (0.40) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869772 0.90 EGFR (0.40) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869676 0.90 GRIA1 (0.40) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869809 0.89 GRIA1 (0.39) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869804 0.88 GRIA1 (0.42) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869508 0.87 GRIA1 (0.42) GRIA1EGFRGSK3BCDK5DYRK1A
SCHEMBL30869734 0.85 EGFR (0.55) GRIA1EGFRGSK3BCDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 EP disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 GRIA1 484/4885EGFR 1355/4885GSK3B 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.